Private company

Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in New York, New York.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York, New York1
  • Incorporated inDE2
  • Business address3 East 28Th Street, 10Th Floor, New York, Ny 100162
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income345-$127.4M in 2020+289% since 2017
-$150.0M-$100.0M-$50.0M02017: -$32.7M-$32.7M20172018: -$90.8M-$90.8M2018+177%2019: -$114.9M-$114.9M2019+27%2020: -$127.4M-$127.4M2020+11%
Net income345-$126.3M in 2020+286% since 2017
-$150.0M-$100.0M-$50.0M02017: -$32.7M-$32.7M20172018: -$89.0M-$89.0M2018+172%2019: -$111.8M-$111.8M2019+26%2020: -$126.3M-$126.3M2020+13%
Fiscal year201620172018201920202021
Research and development$27.9M3$79.9M4$104.0M5$117.0M5
Operating income-$32.7M3-$90.8M4-$114.9M5-$127.4M5
Income tax$03$04$05$05
Net income-$32.7M3-$89.0M4-$111.8M5-$126.3M5

Compare Odonate Therapeutics, Inc. with another company

Corporate structure

Odonate Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Odonate Therapeutics, Inc.

  • Ikarian Capital, LLC Filed SC 13G/A on Odonate Therapeutics, Inc., latest Feb 14, 2022
  • Janus Henderson Group Ltd. Filed SC 13G/A on Odonate Therapeutics, Inc., latest Feb 10, 2022
  • BML Investment Partners, L.P. Filed SC 13G/A on Odonate Therapeutics, Inc., latest Jan 28, 2022 (2 filings since Jan 28, 2022)
  • EcoR1 Capital, LLC Filed SC 13G/A on Odonate Therapeutics, Inc., latest Dec 10, 2021 (2 filings since Nov 18, 2021)
  • Boxer Capital, LLC Filed SC 13D/A on Odonate Therapeutics, Inc., latest Nov 26, 2021 (2 filings since Nov 22, 2021)
  • TANG CAPITAL PARTNERS LP Filed SC 13D/A on Odonate Therapeutics, Inc., latest Nov 19, 2021
  • Odonate Therapeutics, Inc. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Odonate Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.4M5 Dec 31, 2020$2.4M5 Dec 31, 2019+43.6%
Accumulated depreciation$1.1M5 Dec 31, 2020$698.0K5 Dec 31, 2019+58.2%
Property and equipment, net$2.3M5 Dec 31, 2020$1.7M5 Dec 31, 2019+37.5%
Operating-lease assets (leased space)$4.0M5 Dec 31, 2020$1.6M5 Dec 31, 2019+154.1%

Leadership

Who has led Odonate Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kevin C. Tang2017–2021

Chief financial officer

  1. John G. Lemkey2018
  2. Michael S. Hearne2018–2021

Chief operating officer

  1. Robert D. Millham2017–2018
  2. John G. Lemkey2018–2020
20202025
Board members and other officers (8)

Former names

  • Odonate Therapeutics, LLCSep 29, 2017 to Dec 6, 20172

Timeline

  1. Jan 7, 20228-K Listing notice or transfer17
  2. Nov 18, 20218-K Other events18
  3. Dec 6, 2017New chief executive Kevin C. Tang becomes CEO6

Filings

27 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 6 insider forms, 9 large holders, 9 other. The latest 20:

  1. Feb 14, 2022SC 13G/A EDGAR
  2. Feb 10, 2022SC 13G/A JANUS HENDERSON GROUP PLC OWNS 0% EDGAR
  3. Feb 7, 202215-12B EDGAR
  4. Jan 28, 2022EFFECT EDGAR
  5. Jan 28, 2022EFFECT EDGAR
  6. Jan 28, 2022EFFECT EDGAR
  7. Jan 28, 2022SC 13G/A NONE EDGAR
  8. Jan 28, 2022SC 13G NONE EDGAR
  9. Jan 26, 2022S-8 POS EDGAR
  10. Jan 26, 2022POS AM EDGAR
  11. Jan 26, 2022S-8 POS EDGAR
  12. Jan 26, 2022POS AM EDGAR
  13. Jan 26, 2022POS AM EDGAR
  14. Jan 7, 20228-K EDGAR
  15. Dec 10, 20214 EDGAR
  16. Dec 10, 2021SC 13G/A EDGAR
  17. Nov 26, 2021SC 13D/A EDGAR
  18. Nov 24, 20214 FORM 4 SUBMISSION EDGAR
  19. Nov 22, 2021SC 13D/A EDGAR
  20. Nov 19, 2021SC 13D/A AMENDMENT NO. 7 EDGAR

The 27 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 1 buys and 14 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 10, 2021EcoR1 Capital, LLC10% ownerSale5,545,000$1.65$9.1MForm 4
Dec 9, 2021EcoR1 Capital, LLC10% ownerSale156,669$1.82$285.1KForm 4
Dec 1, 2021EcoR1 Capital, LLC10% ownerBuy185,941$1.66$308.7KForm 4
Dec 1, 2021EcoR1 Capital, LLC10% ownerSale185,941$1.66$308.7KForm 4
Nov 24, 2021Boxer Capital, LLC10% ownerSale200,000$1.57$314.0KForm 4
Nov 22, 2021Boxer Capital, LLC10% ownerSale200,000$1.55$310.0KForm 4
Nov 19, 2021TANG CAPITAL MANAGEMENT LLC10% ownerSale365,289$1.92$701.4KForm 4
Nov 19, 2021Davis Aaron I.DirectorSale180,000$1.85$333.6KForm 4
Nov 19, 2021Boxer Capital, LLC10% ownerSale150,000$1.84$276.0KForm 4
Nov 18, 2021TANG CAPITAL MANAGEMENT LLC10% ownerSale1,094,265$1.90$2.1MForm 4
Nov 18, 2021Davis Aaron I.DirectorSale250,000$1.95$487.5KForm 4
Nov 18, 2021Boxer Capital, LLC10% ownerSale250,000$1.95$487.5KForm 4
Nov 17, 2021TANG CAPITAL MANAGEMENT LLC10% ownerSale1,287,577$2.29$3.0MForm 4
Nov 17, 2021Davis Aaron I.DirectorSale770,000$2.18$1.7MForm 4
Nov 17, 2021Boxer Capital, LLC10% ownerSale600,000$2.17$1.3MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Odonate Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROdonate Therapeutics, Inc.1
  • CIK0001717452
  • Employer ID (EIN)82-24930651
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address3 East 28Th Street, 10Th Floor, New York, NY 100161
  • Phone332-206-09351
  • Shares outstanding38,490,336 as of Oct 29, 202125
  • Public float$566.4M as of Jun 30, 20205
  • On EDGAR sinceSep 29, 20171
  • Filings405 in all: 4 (270), 8-K (22), 3 (13), SC 13D/A (13), 10-Q (12), SC 13G/A (9), CORRESP (7), EFFECT (7)1
    All 31 form types

    SC 13G (7), 424B5 (5), UPLOAD (5), 10-K (4), DEF 14A (4), POS AM (3), S-3 (3), SC 13D (3), DRSLTR (2), S-8 (2), S-8 POS (2), 10-K/A (1), 15-12B (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), CT ORDER (1), DRS (1), DRS/A (1), S-1 (1), S-1/A (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Feb 23, 2021
    Quarterly report (10-Q) Nov 10, 2021
    Proxy statement (DEF 14A) Jun 1, 2021
    Latest 8-K (8-K) Jan 7, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    SEC EDGAROther events
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25